Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.96 EUR | +0.23% |
|
-0.58% | +10.51% |
| 06-30 | NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation |  |
| 06-05 | Eurofins Scientific SE acquired High North Laboratories. | CI |
| Market Cap | 12.05B 13.78B 11.12B 10.27B 19.48B 1,314B 19.81B 133B 52.15B 647B 51.73B 50.6B 2,225B | P/E 2026 * |
23.9x | P/E 2027 * | 18.4x |
|---|---|---|---|---|---|
| Enterprise Value | 15.49B 17.71B 14.29B 13.2B 25.04B 1,689B 25.46B 171B 67.05B 832B 66.5B 65.06B 2,861B | EV / Sales 2026 * |
2.04x | EV / Sales 2027 * | 1.87x |
| Free-Float |
58.35% | Yield 2026 * |
1.12% | Yield 2027 * | 1.3% |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.23% | ||
| 1 week | -0.58% | ||
| Current month | +0.58% | ||
| 1 month | +5.41% | ||
| 3 months | +7.48% | ||
| 6 months | -0.46% | ||
| Current year | +10.51% |
| 1 week | 66.6 |  | 70.28 |
| 1 month | 61.44 | | 70.28 |
| Current year | 56.84 | | 74.32 |
| 1 year | 54.86 | | 74.32 |
| 3 years | 39.47 | | 74.32 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-27 | Buy | 700 | 0.0004% | |||
| 04-19 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 04-19 | Fiscal year | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.23% | -0.58% | +13.76% | +21.11% | 13.78B | |
| +0.58% | +2.06% | +2.92% | +10.86% | 50.73B | |
| -2.22% | -1.25% | +385.40% | +586.81% | 39.73B | |
| -0.54% | +0.39% | +25.57% | -5.28% | 34.69B | |
| -1.36% | +0.35% | +17.88% | +55.14% | 33.21B | |
| +1.21% | -4.58% | +3.00% | +35.46% | 26.76B | |
| -1.81% | -1.48% | - | - | 16.8B | |
| +0.51% | -3.47% | +63.97% | +122.60% | 15.37B | |
| -0.62% | -3.09% | +10.29% | -31.35% | 12.85B | |
| +0.24% | -8.96% | +1,640.79% | +665.26% | 12.11B | |
| Average | -0.38% | -1.64% | +240.40% | +162.29% | 25.6B | |
| Weighted average by Cap. | -0.45% | -0.64% | +159.68% | +151.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.6B 8.69B 7.01B 6.47B 12.28B 829B 12.49B 83.76B 32.89B 408B 32.62B 31.91B 1,403B | 8.07B 9.23B 7.45B 6.88B 13.05B 880B 13.27B 88.98B 34.94B 434B 34.66B 33.91B 1,491B |
| Net income | 517M 591M 477M 440M 835M 56.34B 849M 5.69B 2.24B 27.75B 2.22B 2.17B 95.41B | 676M 773M 624M 576M 1.09B 73.73B 1.11B 7.45B 2.93B 36.32B 2.9B 2.84B 125B |
| Net Debt | 3.44B 3.94B 3.17B 2.93B 5.56B 375B 5.66B 37.93B 14.9B 185B 14.78B 14.45B 636B | 3.08B 3.53B 2.85B 2.63B 4.99B 336B 5.07B 33.99B 13.35B 166B 13.24B 12.95B 570B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | €68.96 | +0.23% | 233,361 |
| 09/07/26 | €68.80 | +2.59% | 280,414 |
| 08/07/26 | €67.06 | -2.70% | 226,836 |
| 07/07/26 | €68.92 | +0.32% | 205,550 |
| 06/07/26 | €68.70 | -0.95% | 244,138 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
